Exosome-mediated delivery of miR-30a sensitize cisplatin-resistant variant of oral squamous carcinoma cells via modulating Beclin1 and Bcl2.
autophagy
chemoresistance
exosomes
miRNA30a-5p
oral cancer
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
19 May 2020
19 May 2020
Historique:
received:
16
11
2019
accepted:
19
03
2020
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
6
6
2020
Statut:
epublish
Résumé
Exosomes facilitate cross-talk amongst tumor cells, and thus also possess the potential to influence tumor-microenvironment and chemo-resistance. miRNAs, the important constituent of exosomes, are often dysregulated in cancer. They have been shown to play an essential role in tumor progression, metastasis, invasion, and resistance developed against different therapies. Acquisition of cisplatin-chemoresistance remains a major hurdle in the effective treatment of oral squamous cell carcinoma (OSCC). In this study, we demonstrate the importance of exosome-mediated miR-30a transfer in conferring cisplatin sensitivity in the otherwise resistant OSCC cells. Notably, miR-30a was found to be significantly reduced in exosomes isolated from the serum of OSCC patients, especially those having disease-recurrence, post cisplatin treatment. In conjunction with the findings in clinical samples, decreased miR-30a expression was observed
Identifiants
pubmed: 32499869
doi: 10.18632/oncotarget.27557
pii: 27557
pmc: PMC7244014
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1832-1845Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors declare no conflicts of interest.
Références
Am J Cancer Res. 2018 Sep 01;8(9):1661-1673
pubmed: 30323961
Adv Wound Care (New Rochelle). 2018 Sep 1;7(9):299-308
pubmed: 30263873
Cancer Med. 2015 May;4(5):745-58
pubmed: 25684390
Cell Rep. 2017 Apr 11;19(2):375-388
pubmed: 28402859
J Oral Maxillofac Pathol. 2018 Jan-Apr;22(1):18-26
pubmed: 29731552
J Biol Chem. 2012 Oct 26;287(44):37570-82
pubmed: 22955280
Carcinogenesis. 2008 May;29(5):1022-32
pubmed: 18321868
Oncol Rep. 2017 Sep;38(3):1613-1620
pubmed: 28713923
J Proteome Res. 2009 Jan;8(1):113-7
pubmed: 19072545
Am J Cancer Res. 2018 Mar 01;8(3):354-365
pubmed: 29636994
Theranostics. 2017 Jan 26;7(3):789-804
pubmed: 28255367
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W169-73
pubmed: 23680784
J Oncol. 2019 Oct 13;2019:8585276
pubmed: 31737071
Biochem Biophys Res Commun. 2012 Jun 15;422(4):764-9
pubmed: 22627130
Medicines (Basel). 2015 Dec;2(4):310-327
pubmed: 27088079
Expert Opin Ther Targets. 2013 Sep;17(9):1073-80
pubmed: 23865553
Cancers (Basel). 2015 Dec 18;7(4):2466-85
pubmed: 26694467
Cell Physiol Biochem. 2017;43(3):1126-1139
pubmed: 28977798
Cell Death Dis. 2019 Feb 15;10(3):153
pubmed: 30770779
Pancreat Disord Ther. 2016;6(2):e148
pubmed: 27030812
Cell Immunol. 2014 Nov-Dec;292(1-2):65-9
pubmed: 25290620
Genes Cancer. 2018 Mar;9(3-4):87-100
pubmed: 30108680
Biomed Res Int. 2014;2014:179486
pubmed: 24963475
Cancer Lett. 2018 Nov 1;436:10-21
pubmed: 30102952
Oral Oncol. 2007 Aug;43(7):701-12
pubmed: 17112776
PLoS One. 2015 Oct 27;10(10):e0141308
pubmed: 26506105
J Mol Med (Berl). 2017 Aug;95(8):861-871
pubmed: 28487996
BMC Cancer. 2018 Apr 11;18(1):404
pubmed: 29642855
Sci Rep. 2018 Jan 16;8(1):829
pubmed: 29339789
Cell Death Dis. 2018 Oct 19;9(11):1070
pubmed: 30341283
Semin Immunol. 2018 Feb;35:69-79
pubmed: 29289420
Adv Clin Chem. 2016;74:103-41
pubmed: 27117662
J Cell Commun Signal. 2014 Jun;8(2):147-56
pubmed: 24464300
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818763450
pubmed: 29681222
J Oncol. 2018 Aug 6;2018:5167829
pubmed: 30158978
Mol Cancer. 2019 Mar 19;18(1):43
pubmed: 30890168
Cell Physiol Biochem. 2017;41(4):1616-1632
pubmed: 28359057
Mol Cancer. 2019 Mar 1;18(1):32
pubmed: 30823926
Biosci Rep. 2018 Jan 25;38(1):
pubmed: 29026005
Front Oncol. 2017 Apr 18;7:65
pubmed: 28459042
Int J Mol Med. 2016 May;37(5):1274-80
pubmed: 26986233
Drug Discov Today. 2019 Oct;24(10):2058-2067
pubmed: 31228614
Adv Biol Regul. 2015 Jan;57:1-9
pubmed: 25294678
PLoS One. 2018 Nov 29;13(11):e0208044
pubmed: 30496316
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W451-4
pubmed: 16845047
J Biol Chem. 2012 Feb 3;287(6):4148-56
pubmed: 22157765
Sci Rep. 2016 Apr 05;6:23932
pubmed: 27045798
BMC Cancer. 2018 May 2;18(1):504
pubmed: 29720111
Mol Cancer. 2016 Apr 07;15:28
pubmed: 27056547
J Clin Oncol. 2013 Feb 20;31(6):744-51
pubmed: 23129742
Theranostics. 2018 Oct 22;8(19):5259-5275
pubmed: 30555545
Oncotarget. 2015 Oct 6;6(30):29877-88
pubmed: 26337469
Elife. 2015 Aug 12;4:
pubmed: 26267216